These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 26408258

  • 1. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J, Durham N, Wetzel L, Rothstein R, Chesebrough J, Holoweckyj N, Zhao W, Leow CC, Hollingsworth R.
    Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
    [Abstract] [Full Text] [Related]

  • 2. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L, Badiee A, Mosaffa F, Jaafari MR.
    J Control Release; 2015 Dec 28; 220(Pt A):275-286. PubMed ID: 26518722
    [Abstract] [Full Text] [Related]

  • 3. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H.
    Clin Cancer Res; 2010 May 15; 16(10):2781-91. PubMed ID: 20460483
    [Abstract] [Full Text] [Related]

  • 4. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B, Pommey S, Smyth MJ, Stagg J.
    Clin Cancer Res; 2013 Oct 15; 19(20):5626-35. PubMed ID: 23983257
    [Abstract] [Full Text] [Related]

  • 5. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z, Wang H, Meng F, Li J, Zhang S.
    J Transl Med; 2015 Jul 29; 13():247. PubMed ID: 26219551
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effective delivery of chemotherapeutic nanoparticles by depleting host Kupffer cells.
    Ohara Y, Oda T, Yamada K, Hashimoto S, Akashi Y, Miyamoto R, Kobayashi A, Fukunaga K, Sasaki R, Ohkohchi N.
    Int J Cancer; 2012 Nov 15; 131(10):2402-10. PubMed ID: 22362271
    [Abstract] [Full Text] [Related]

  • 15. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP, Mandl SJ, dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB.
    Cancer Immunol Immunother; 2016 May 15; 65(5):537-49. PubMed ID: 26961085
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D, Iwai T, Harada S, Suzuki M, Yamamoto K, Sugimoto M.
    Anticancer Res; 2019 Apr 15; 39(4):1749-1760. PubMed ID: 30952714
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.